Inclusion Criteria:

- 18 -75 years, both sex

- ECOG performance status 0-2

- Histologically proven solid cancer, chemotherapy-naïve patient

- Planed to receive cisplatin (≥ 50mg/m2) based, single day chemotherapy,

- No nausea or vomiting within 72 hours prior to chemotherapy

- Serum Cr < 2.5 mg/dl, or calculated CCr ≥ 50 ml/min

- Serum total bilirubin < 2 mg/dl, AST/ALT < 3 times the upper normal limit , ALP < 5
times the upper normal limit

- Absolute neutrophil count ≥ 1,500/μL, platelet ≥ 100,000/μL

- Expected life duration ≥ 3 months

- Patients must sign an informed consent indicating that they are aware of the
investigational nature of the study in keeping with the policy of the hospital

Exclusion Criteria:

- Patients with active infection, severe heart disease, uncontrollable hypertension or
diabetes mellitus, active gastric or duodenal ulcers, or pregnancy or breast-feeding

- Patients who should take steroid, antiemetics, pimozide, terfenadine, astemizole,
cisapride, rifampin, carbamazepine, phenytoin, ketoconazole, itraconazole,
nefazodone, troleandomycin, clarithromycin, ritonavir or nelfinavir for the treatment
of other diseases

- Patients taking any medicine, which could affect study results, within 1 week before
chemotherapy (or taking anti-emetics within 48 hours before chemotherapy). Prior to
beginning chemotherapy, single-agent benzodiazepines as hypnotic is allowed, but it
can't be receiving during day 1-6 of 1st chemotherapy cycle.

- Patients with symptomatic brain metastasis

- Patients with GI obstruction or other diseases that could provoke nausea and vomiting

- Patients receiving RT on brain, abdomen or pelvis within 2 weeks before chemotherapy

- Patients who cannot understand informed consent or express his/her condition

- Patients who cannot swallow drugs

- Patients who have known allergy or severe side effect on study drugs